5 research outputs found
Fibrosis miocárdica maligna en la insuficiencia cardiaca con fracción de eyección preservada de origen hipertensivo. Influencia de la enfermedad renal crónica
La tesis tratar de esclarecer el papel de la fibrosis miocárdica en pacientes con HTA desde estadíos tempranos de la enfermedad. Acorde con ello se pretende detectar aquellos pacientes con peor pronóstico clínico. Por otra parte, se analiza la posible interacción de la ERC en la progresión de fibrosis miocárdica y en la disfunción diastólica en pacientes hipertensos
Fibrosis miocárdica maligna en la insuficiencia cardiaca con fracción de eyección preservada de origen hipertensivo. Influencia de la enfermedad renal crónica
La tesis tratar de esclarecer el papel de la fibrosis miocárdica en pacientes con HTA desde estadíos tempranos de la enfermedad. Acorde con ello se pretende detectar aquellos pacientes con peor pronóstico clínico. Por otra parte, se analiza la posible interacción de la ERC en la progresión de fibrosis miocárdica y en la disfunción diastólica en pacientes hipertensos
[Myocarditis related SARS-CoV-2 infection or vaccination: an expert consensus statement on its diagnosis and management].
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has revealed several cardiovascular complications, including myocarditis caused by SARS-CoV-2 infection (COVID-19) or after messenger RNA vaccine administration. Because of the high prevalence of COVID-19, the expansion of vaccination programs, and the appearance of new information on myocarditis in these contexts, there is a need to condense the knowledge acquired since the start of the pandemic. To meet this need, this document was drafted by the Myocarditis Working Group of the Heart Failure Association of the Spanish Society of Cardiology, with the collaboration of the Spanish Agency for Medicines and Health Products (AEMPS). The document aims to address the diagnosis and treatment of cases of myocarditis associated with SARS-CoV-2 infection or messenger RNA vaccine administration.S
Does chronic kidney disease facilitate malignant myocardial fibrosis in heart failure with preserved ejection fraction of hypertensive origin?
In hypertensive patients with heart failure (HF) a serum biomarker combination of high
carboxy-terminal propeptide of procollagen type-I (PICP) and low carboxy-terminal telopeptide
of collagen type-I to matrix metalloproteinase-1 (CITP:MMP-1) ratio identifies a histomolecular
phenotype of malignant myocardial fibrosis (mMF) associated with severe diastolic dysfunction
(DD) and poor outcomes. As chronic kidney disease (CKD) facilitates MF and DD, we investigated
the influence of CKD on the mMF biomarker combination in HF patients with preserved ejection
fraction (HFpEF). Hypertensives (n = 365), 232 non-HF and 133 HFpEF, were studied, and 35%
non-HF and 46% HFpEF patients had CKD (estimated glomerular filtration rate < 60 mL/min/1.73 m2
or urine albumin-to-creatinine ratio ≥ 30 mg/g). Specific immunoassays were performed to determine
biomarkers. Medians were used to establish the high PICP and low CITP:MMP-1 combination.
A comparison with non-HF showed that the biomarker combination presence was increased in
HFpEF patients, being associated with CKD in all patients. CKD influenced the association of
the biomarker combination and HFpEF (p for interaction ≤ 0.019). The E:e’ ratio was associated
with the biomarker combination in CKD patients. Among CKD patients with HFpEF, those with
the biomarker combination exhibited higher (p = 0.016) E:e’ ratio than those without the pattern.
These findings suggest that CKD facilitates the development of biomarker-assessed mMF and DD in
hypertensive HFpEF patients
Does chronic kidney disease facilitate malignant myocardial fibrosis in heart failure with preserved ejection fraction of hypertensive origin?
In hypertensive patients with heart failure (HF) a serum biomarker combination of high
carboxy-terminal propeptide of procollagen type-I (PICP) and low carboxy-terminal telopeptide
of collagen type-I to matrix metalloproteinase-1 (CITP:MMP-1) ratio identifies a histomolecular
phenotype of malignant myocardial fibrosis (mMF) associated with severe diastolic dysfunction
(DD) and poor outcomes. As chronic kidney disease (CKD) facilitates MF and DD, we investigated
the influence of CKD on the mMF biomarker combination in HF patients with preserved ejection
fraction (HFpEF). Hypertensives (n = 365), 232 non-HF and 133 HFpEF, were studied, and 35%
non-HF and 46% HFpEF patients had CKD (estimated glomerular filtration rate < 60 mL/min/1.73 m2
or urine albumin-to-creatinine ratio ≥ 30 mg/g). Specific immunoassays were performed to determine
biomarkers. Medians were used to establish the high PICP and low CITP:MMP-1 combination.
A comparison with non-HF showed that the biomarker combination presence was increased in
HFpEF patients, being associated with CKD in all patients. CKD influenced the association of
the biomarker combination and HFpEF (p for interaction ≤ 0.019). The E:e’ ratio was associated
with the biomarker combination in CKD patients. Among CKD patients with HFpEF, those with
the biomarker combination exhibited higher (p = 0.016) E:e’ ratio than those without the pattern.
These findings suggest that CKD facilitates the development of biomarker-assessed mMF and DD in
hypertensive HFpEF patients